Mitochondrial Glutathione & Breast Cancer Metastasis

Mitochondrial Metabolism and Cancer metastasis: Teh Role of Glutathione

The mitochondria, often dubbed the “powerhouse of the cell,” are increasingly recognized as key players in cancer progress and progression. New research illuminates a critical link between a mitochondrial metabolite, glutathione, and the ability of breast cancer cells to metastasize – to break away from the primary tumor, travel through the body, and establish new tumors in distant tissues. This discovery offers a possibly new target for cancer therapies.

Understanding Metastasis: The Deadliest Stage of Cancer

The vast majority of cancer-related deaths aren’t caused by the primary tumor itself, but by its spread – a process called metastasis. This complex process involves cancer cells detaching from the original tumor, entering the bloodstream or lymphatic system, traveling to distant sites, and forming new colonies.Identifying the factors that enable metastasis is thus paramount in the fight against cancer.

Metabolites – small molecules involved in metabolism – have emerged as important regulators of metastasis. Previous studies have shown that metabolites like lactate, pyruvate, glutamine, and serine each contribute to different stages of the metastatic process. Given that mitochondria are central to cellular metabolism and produce many of these metabolites, it’s logical that mitochondrial activity plays a role in cancer spread. Recent studies have already linked mitochondrial function to metastasis in breast, renal, and pancreatic cancers, but the precise mechanisms remained unclear.

“Mitochondria have thousands of metabolites, and it’s been difficult to determine which are important to tumor formation and growth, and which initiate metastasis,” explains Kivanç Birsoy, head of the Laboratory of Metabolic Regulation and Genetics at Rockefeller University.

Identifying Glutathione as a Key Metastatic Driver

To overcome this challenge, Birsoy and his team developed an innovative approach using protein tagging to distinguish between primary tumor cells and those that had already metastasized to the lungs. They then analyzed the metabolites within the mitochondria of these cells to identify differences in their metabolic profiles. This unbiased approach revealed a striking finding: levels of glutathione, a major antioxidant, where significantly elevated in metastatic cancer cells that had invaded the lung.

To confirm this observation, the researchers employed spatial metabolomics, a technique that allows them to visualize the distribution of glutathione directly within lung tissue. This confirmed that glutathione was indeed concentrated in metastatic cancer cells within the lung habitat.

Further inquiry focused on mitochondrial membrane proteins, specifically looking for transporters that were essential for the growth of metastatic cells in the lung. The results pointed to SLC25A39, the mitochondrial glutathione transporter, as a key player. This finding established a direct link between a metabolite (glutathione) and its transporter (SLC25A39) in driving cancer metastasis.

How Glutathione Fuels Metastasis: Beyond Antioxidant activity

The researchers then delved into the mechanism by which mitochondrial glutathione promotes cancer spread. surprisingly, they found that it wasn’t acting as an antioxidant – a function typically associated with glutathione. Instead, glutathione was found to activate ATF4, a transcription factor that helps cancer cells survive in low-oxygen conditions, a common characteristic of metastatic sites.

This pinpointed the specific timing of glutathione’s importance: during the early stages of metastatic colonization,when cancer cells are adapting to the stressful environment of a new tissue.This suggests that targeting glutathione during this critical window could be particularly effective in preventing metastasis.

Building on Previous discoveries

This research builds upon previous work from birsoy’s lab. in 2021, his team first identified SLC25A39 as the transporter responsible for bringing glutathione into the mitochondria. in 2023,they demonstrated that SLC25A39 isn’t just a transporter,but a dynamic sensor that regulates glutathione levels within the mitochondria,adjusting them based on cellular needs. Having already characterized this transporter, the team was well-equipped to investigate its role in cancer metastasis.

“As we found this transporter earlier and knew how to block the entry of glutathione, we already had the tools necesary to investigate its role in cancer metastasis.”

Clinical Implications and Future Directions

The findings have potential clinical implications. Analysis of breast cancer samples from patients whose disease had spread to the lung revealed elevated levels of SLC25A39. furthermore, higher SLC25A39 expression was strongly correlated with poorer overall survival in these patients. This suggests that SLC25A39 could serve as a biomarker for predicting metastasis and identifying patients who might benefit from targeted therapies.

The ultimate goal is to develop a small molecule drug that specifically targets SLC25A39, blocking the import of glutathione into mitochondria and thereby preventing metastasis. Such a targeted approach could offer fewer side effects compared to conventional cancer therapies that broadly target cellular processes.

However,birsoy emphasizes the importance of understanding the intricate interplay of metabolites within different cellular compartments. “We’re trying to make our knowledge of metabolism more precise,” he says. “It’s not just about some metabolite levels going up and others going down.We need to look at the organelles, the precise compartments, to understand how metabolites influence human health.”

Data Summary: SLC25A39 Expression and Patient Survival

Source:

Journal reference: